Q32 Bio’s Bempikibart Targets Alopecia Areata with Safety-Focused Strategy

Q32 Bio, a biotech company developing treatments for alopecia areata and related dermatological conditions, highlighted its lead compound, bempikibart (SIGNAL-AA Part B), during a presentation at the Wells Fargo 21st Annual Healthcare Conference. The stock, which closed at $11.69 on September 8, 2026, had declined 16.5% over the prior week but remained up 585% year-to-date, reflecting Wall Street’s bullish outlook with price targets ranging from $34 to $59. The company’s market capitalization stood at $347 million, underscoring its growth trajectory despite recent volatility.